The University of Michigan Frankel Cardiovascular Center is one of the nation's first hospitals to use the Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) System, the smallest implantable cardiac monitoring device available.
Smaller than a key, the cardiac monitor is inserted just beneath the skin in the upper chest area, and continuously records heart rhythms over long periods of time.
With the device, physicians can help patients find answers to unexplained fainting or other potential heart-related problems without interrupting the patient's lifestyle.
"The amount of data generated by the device allows us to more accurately correlate what a patient describes they are feeling with their specific rhythm," says Eric Good, D.O., assistant professor of internal medicine and electrophysiology specialist at the U-M Health System. "As a result, it improves our ability to tailor a treatment plan to address their unique heart issue."
The Reveal LINQ ICM is indicated for patients who experience dizziness, palpitation, syncope (fainting), or chest pain that may suggest a cardiac arrhythmia, and for patients at increased risk for cardiac arrhythmias.
The simplified procedure, small size and insertion tools make the device faster and easier for physicians to implant, which may expand access to more patients needing long-term monitoring. The ICM is often nearly invisible to the naked eye once inserted.
Conventional heart monitors attach to the outside of the body for 24 hours or up to 30 days, have visible wires and are often associated with skin irritation and rashes, which limit compliance.
The new option in cardiac monitoring gained FDA approval in late February and in addition to its continuous and wireless monitoring capabilities, the system provides remote monitoring. Through the Carelink Network, physicians can request notifications to alert them if their patients have had cardiac events.
The Reveal LINQ ICM is MR-Conditional, allowing patients to undergo magnetic resonance imaging (MRI) if needed.